Trends in Drug Discovery in Diabetes and Obesity
$248.81
- Hardcover
320 pages
- Release Date
14 October 2026
Summary
Intended as an introduction for scientists and professionals working in drug discovery and development, the first part of the book reviews recent therapy developments in diabetes and obesity treatment.
The second part surveys important drug classes, including both peptide drugs and small molecule drugs such as GLP-1 receptor agonists, GIP antagonists and poly-agonists.
The last part of the book is devoted to selected case studies which provide insights into the discovery of re…
Book Details
| ISBN-13: | 9783527353309 |
|---|---|
| ISBN-10: | 3527353305 |
| Author: | Lars Linderoth, Soren Ostergaard, János Fischer, Christian Klein, Wayne E. Childers, David P. Rotella |
| Publisher: | Wiley-VCH Verlag GmbH |
| Imprint: | Blackwell Verlag GmbH |
| Format: | Hardcover |
| Number of Pages: | 320 |
| Release Date: | 14 October 2026 |
| Dimensions: | 170mm x 244mm |
| Series: | Trends in Drug Discovery |
Lars Linderoth
Lars Linderoth
Lars Linderoth received his PhD in Chemistry in 2008 from the Technical University of Denmark (DTU). His doctoral research focused on enzyme-triggered drug delivery under the supervision of Professors Thomas Andresen, Günther Peters, and Robert Madsen. In 2008, he joined Novo Nordisk as a postdoctoral researcher for two years, subsequently transitioning to a Research Scientist role. Lars has remained at Novo Nordisk, where he currently serves as a Director. He has managed various departments within research chemistry in Denmark and has authored numerous publications. He is also named as an inventor on several patents in the field of drug discovery.
Søren Østergaard
Søren Østergaard earned his PhD in Chemistry in 1996 from the University of Copenhagen. His doctoral work involved the design of peptide and peptidomimetic ligands for protein targets, with applications in the study of protein-protein interactions. Following an assistant professorship, he joined Novo Nordisk in 1997. Søren is currently a Principal Scientist with extensive experience in peptide drug discovery. He has authored over 45 publications and is named as an inventor on more than 20 patents.
Returns
This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.